The report states the deal was "intended to foster an investment climate favourable to pharmaceutical research and development in Canada. However, the percentage of R&D to sales by pharmaceutical patentees in Canada has been falling since the late 1990s." The Toronto physician and York University professor said despite the industry's claims, patented drug companies have been winding down their research presence in Canada for years now. These are also countries where large patented drug makers are headquartered. The statement was made as part of a long-awaited regulatory change to how the PMPRB calculates fair prices for patented drugs.

Source: CBC News December 01, 2017 19:57 UTC